Avalyn Pharma
Revolutionizing respiratory care with every breath
58 employees · est. 2011 · Boston, United States
Syntara
Syntara (ASX:SNT) is an ASX-listed clinical stage drug developer for diseases linked to fibrosis and inflammation.
58 employees · est. 1998 · Australia
Syntara is the older company (2011 vs 1998).
Side-by-Side Comparison
| Metric | Avalyn Pharma | Syntara |
|---|---|---|
| Founded | ||
| Founded | 2011 | 1998 older |
| Headquarters | ||
| Headquarters | Boston, United States | Australia |
| Employees | ||
| Employees | 58 | 58 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Pharmaceutical | Biotechnology, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series C | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $272.50M | $1.39M |
| Funding Rounds | ||
| Funding Rounds | 3 | 1 |
| Services | ||
| Services | Development of inhaled therapies, Drug delivery solutions, Clinical trials | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with rare lung diseases, Healthcare providers, Biopharmaceutical investors | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Pulmonary Fibrosis Treatment, Respiratory Care, Inhaled Formulations, Interstitial Lung Diseases, Pirfenidone, Nintedanib, Idiopathic Pulmonary Fibrosis, Biopharma Company, Therapeutics Development, Lung Exposure, Systemic Exposure Reduction, Phase 2b MIST Study, Optimized Inhaled Therapies, Severe Respiratory Diseases, Drug Formulation | Clinical Stage Drug Development, Extracellular Matrix Dysfunction, Amine Oxidase Chemistry, Drug Candidates, Fibrotic Diseases, Inflammatory Diseases, Blood Cancers, Respiratory Products, Royalties, Neuroinflammation, Chronic Fibrosis, Haematological Malignancies, Myelofibrosis, Myelodysplastic Syndrome, Scar Management |
| Website | ||
| Website | avalynpharma.com | syntaratx.com.au |
About Avalyn Pharma
Avalyn Pharma, founded in 2011 and headquartered in the United States, is pioneering advancements in the treatment of pulmonary fibrosis. With the slogan, “Revolutionizing respiratory care with every breath,” Avalyn is focused on creating innovative inhaled therapies. The company is reshaping respi...
About Syntara
Syntara (ASX:SNT) is a clinical stage drug developer focusing on diseases associated with fibrosis and inflammation. The company, founded in 1998, specializes in targeting extracellular matrix dysfunction using its expertise in amine oxidase chemistry. Its lead candidate SNT-5505 has received FDA Or...
We will tell you when either one moves
BounceWatch watches Avalyn Pharma and Syntara for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Avalyn Pharma and Syntara — by email.
Frequently Asked Questions
Compare Avalyn Pharma with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Avalyn Pharma on 11 Mar 2026, and Syntara on 6 Dec 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.